Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
: CD36 and YKL-40 may be potential inflammatory biomarkers for early onset of atherosclerosis in patients with T2DM.
|
29806605 |
2018 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
CD36 and atherosclerosis.
|
11048891 |
2000 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
CD36, a scavenger receptor, plays an important role in the progression of atherosclerosis through its interaction with oxidized low-density lipoprotein (ox-LDL).
|
27234131 |
2016 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
CD36 expression in peripheral blood mononuclear cells reflects the onset of atherosclerosis.
|
28677864 |
2018 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
CD36 overexpression: a possible etiopathogenic mechanism of atherosclerosis in patients with prediabetes and diabetes.
|
28729885 |
2017 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
CD36 has been reported to participate in atherosclerosis process and miR-135a mimics can inhibit its expression while miR-135a inhibitors exhibited a reverse phenomenon.
|
29663503 |
2018 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
CD36 has been involved in atherosclerosis progression and it was found that overexpression of miR-181a inhibited its protein levels.
|
29737518 |
2018 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
CD36 is associated with regulation of lipid metabolism, atherosclerosis, and blood pressure.
|
31185924 |
2019 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Accordingly, paeonol retarded the progress of atherosclerosis in ApoE(‑/‑) mice and modulated the expression of CD36 and ABCA1 in aortas similarly to that observed in macrophages.
|
25405950 |
2015 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Adipocytokines such as tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), adiponectin, leptin, resistin along with peroxisome proliferator activated receptor-γ (PPAR-γ) are important mediators in glucose homeostasis in association with CD36 and can be used as markers for T2DM and atherosclerosis.
|
21262584 |
2011 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression.
|
31815869 |
2019 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Azapeptide analogues of growth hormone-releasing peptide-6 (His-d-Trp-Ala-Trp-d-Phe-Lys-NH<sub>2</sub>, GHRP-6) have for example been pursued as ligands of the cluster of differentiation 36 receptor (CD36) and show promising activity for the development of treatments for angiogenesis-related diseases, such as age-related macular degeneration, as well as for atherosclerosis.
|
28598597 |
2017 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Because CD36 is an essential component of atherosclerosis, defining the function of CD36 and its corresponding signaling pathway may lead to a new treatment strategy for atherosclerosis.
|
24903227 |
2014 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Blocking Wnt5a signaling decreases CD36 expression and foam cell formation in atherosclerosis.
|
29474941 |
2018 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Both persistent up-regulation of CD36 and deficiency of CD36 increase the risk for atherosclerosis.
|
29534172 |
2018 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Both S100A12 and CD36 are implicated in vascular inflammation and atherosclerosis.
|
28756107 |
2019 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Correlation between the anti-CD36 activity of these inhibitors and the known pathophysiological activity of this scavenger receptor in the development of atherosclerosis and diabetes were observed at pharmacological doses.
|
22662181 |
2012 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Cross-sectional studies have shown correlations between plasma CD36 and atherosclerosis but no prospective study has examined the association yet.
|
30218892 |
2018 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Deficiency of CD36 on hematopoietic cells diminished the effect of air pollution on 7-KCh accumulation, foam cell formation, and atherosclerosis.
|
25186795 |
2014 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
During foam cell formation and atherosclerosis development, the scavenger receptor CD36 plays critical roles in lipid uptake and triggering of atherogenicity via the activation of Vav molecules.
|
31570505 |
2019 |
Atherosclerosis
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis.
|
19144874 |
2009 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
EP80317 is an hexapeptide that serves as a ligand for CD36 and features protective effects under conditions such as atherosclerosis and vascular inflammation.
|
30886580 |
2019 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Evaluation of lesion development in these animals will allow us to assess the in vivo contribution of CD36 to the pathogenesis of atherosclerosis.
|
10865832 |
2000 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Functionally, MT4-MMP-null Mafb+AIM+ peritoneal macrophages express higher AIM and scavenger receptor CD36, are more resistant to apoptosis, and bind acLDL avidly, all of which contribute to atherosclerosis.
|
29500407 |
2018 |
Atherosclerosis
|
0.300 |
Biomarker
|
disease |
BEFREE |
Genes that are implicated with lipid uptake and atherosclerosis: CD36, SR-BI, and SR-AI/II.Group 3.
|
15753136 |
2004 |